Dyspepsia and the microbiome: time to focus on the small intestineLaurie Zhong, Gerald Holtmann, Linda Fletcher et al.|Gut|2016Cited by 209
Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 declineSusan Branford, Timothy P. Hughes, David T Yeung et al.|Blood|2014Cited by 198